Studies are focused on the pre-clinical development and design of more effective therapeutic approaches to cancer using mouse
tumor model systems.
The next step for the researchers is to demonstrate the viability of this approach to the production and delivery of an anticancer molecule in a whole
tumor model system.
They further investigated this phenotype in a skin
tumor model system, provided by Maria Sibilia from the Institute for Cancer Research of the Medical University of Vienna, and found that deactivating HDAC1 actually accelerates tumor development, while HDAC2 deactivation has no effect.
Not exact matches
«This approach will hopefully lead to better mechanistic predictive
modeling of response and future design of therapies that further take advantage of how the immune
system recognizes
tumors.»
The researchers have identified a compound that reverses the reprogramming and prevents
tumor formation in
model systems.
He and his co-investigators analyzed 66 ultrasound images of
tumors (32 pictures of a single
tumor and 34 of multiple
tumors) inside a plastic
model of a breast to determine the augmented - reality
system's accuracy of measuring
tumor volume.
The mouse
model could also contribute to the further development of immunotherapies — a method in which the body's immune
system is stimulated, so that it intensifies its fight against
tumor cells.
Now, thanks to the new mouse
model, it will be possible to study how renal
tumors are able to develop in an environment with a normal immune
system, and how cancer cells manage to evade the immune
system's attacks.
We describe an experimental
model system that definitively links surgery and the subsequent wound - healing response to the outgrowth of
tumor cells at distant anatomical sites.
It has been known for decades that warfarin, the most widely used anticoagulant worldwide, reduces
tumor metastasis in
model systems.
This
model showed that in order to detect
tumors 5 millimeters in diameter or smaller in humans, the researchers would need to improve the
system's sensitivity by at least one order of magnitude.
Her work seeks to elucidate the mechanisms and pathways underlying the interaction between the immune
system and cancer using mouse
models that recapitulate the coevolution of
tumor progression and the antitumor immune response.
-- In silico basic and
systems biology: We develop innovative approaches to reverse engineer biological networks from omics data,
model tumor progression at the genomic, transcriptomic and epigenetic level, automatically annotate new proteins and functional elements through integration of complex and heterogeneous data, including data obtained from high - throughput sequencing or time - lapse video - microscopy.
In mouse
models, carcinogen - induced
tumors that arise in immunodeficient mice, when transplanted to wild - type mice, are usually eliminated by the intact immune
system of the new host.
In recent years, a substantial body of evidence from clinical epidemiology and mouse
models has revealed that the immune
system presents a significant barrier to
tumor formation and progression.
Our PDX
models and other next - generation cancer
modeling platforms allow you to address critical questions in oncology research, such as unexplained drug resistance, drug efficacy, genomic heterogeneity in solid
tumor, and the role of the immune
system in drug response.
Drew Pardoll, Glenn Dranoff, Elizabeth Jaffee, Hyam Levitsky, and colleagues conduct preclinical studies showing that a vaccine composed of
tumor cells irradiated and genetically modified to produce immune
system growth factor GM - CSF (granulocyte - macrophage colony - stimulating factor)-- which would become known as the therapeutic cancer vaccine GVAX — could induce potent, specific, and long - lasting anti-
tumor immunity in multiple mouse
tumor models.
Weimin Li: Innovative 3D tissue matrix scaffold
system for
tumor modeling and drug screening
Biocellion is being used to
model a variety of biological
system behaviors, such as biofilm formation and wrinkling, microbial growth dynamics in complex soil structure, brain
tumor growth and invasion, formation of complex bacterial colonies, and changes in blood vessels and skin cells.
She continued to develop these
models and to investigate the molecular and cellular mechanisms underlying human
tumor dormancy as an instructor in Folkman's lab and later as an Assistant Professor at the Center of Cancer
Systems Biology at Tufts University School of Medicine, Boston.
I am currently working with Zika virus and how it affects the T cell response and T cell signaling through
tumor necrosis receptor (TNFR) signaling components OX40, 4 - 1BB, and CD27 in specific mouse
model systems.
These results indicate the importance of assessing miR function in the complex physiology of in vivo
model systems and indicate that further functional testing of miR - 342 is required before concluding it is a bona fide
tumor - suppressor - miR.
They argue that a more appropriate
model, transplanting
tumors from mice into genetically identical hosts with fully intact immune
systems, would be more informative and clinically relevant.
Moreover, knock in animal
models for syngeneic studies and allowing us to isolate transgenic armed effector cells are developed in order to show proof of concept for the diverse applicability of our modular targeting
systems including for
tumor diseases, autoimmune diseases, GvHD, transplantation / rejection as well as viral infections.